Annandale, VA; December 17, 2022
Recent, Encouraging News for People With Recurrent Clostridium difficile (C. diff) infection
The leaders and researchers at Ferring Pharmaceuticals Inc. announced earlier this month Food and Drug Administration (FDA) approval of its microbiota-based therapy for a type of debilitating intestinal infection making it the first drug of its kind for U.S. market. This is also an exciting announcement for the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) because of its role as a clinical research site earlier in 2022. The treatment, called Reybota, is cleared for use in adults 18 and older who have recurrent infections of Clostridioides difficile, or C. diff, and have completed a round of antibiotics. Epidemiological studies indicate that C. diff has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.
“It isn’t often that we see such positive results and so quickly in the research process, stated CARE-ID Medical Director, David Wheeler, MD, FACP, FIDSA. “CARE-ID received its approval to begin recruiting and enrolling participants in March of this year and the process began immediately. In this case, the FDA’s recognition of the importance of this treatment makes us that much more gratified that we were able to participate in this study.